{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:53:32Z","timestamp":1782978812272,"version":"3.54.5"},"reference-count":22,"publisher":"BMJ","issue":"4","funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,2,25]]},"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This analysis examined the association between psoriasis severity, assessed by body surface area (BSA) and the Investigator\u2019s Global Assessment (IGA; previously used only in clinical trials), and patient-reported outcomes (PROs) in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross-sectional analysis within the Corrona Psoriasis Registry, an independent, prospective registry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>70 dermatology practices in the USA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>1529 adult patients with psoriasis being treated with biological or non-biological systemic psoriasis treatment by 31 May 2016.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>\n                      Psoriasis severity was assessed by percentage of affected BSA (mild (0%\u20135%), moderate (&gt;5%\u201310%), severe (&gt;10%\u201315%), very severe (&gt;15%)) and IGA scores (clear\/almost clear (0\u20131), mild (2), moderate (3), severe (4)). PROs (pain, itch, fatigue; Dermatology Life Quality Index [DLQI]; EuroQoL Visual Analogue Scale [EQ-VAS]; Work Productivity and Activity Impairment [WPAI]) were compared across BSA and IGA levels using analysis of variance and X\n                      <jats:sup>2<\/jats:sup>\n                      tests. The association between psoriasis severity and PROs was examined using multivariable regression models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age was 50.6 years and 47% of patients were female. Consistently with more severe psoriasis, symptoms worsened, DLQI scores increased (p&lt;0.05 for each level of BSA and IGA), EQ-VAS decreased (p&lt;0.05 for each level of BSA and IGA) and WPAI scores increased. By BSA score, moderate to very severe psoriasis was associated with poorer outcomes for the \u2018impairment while working\u2019 and \u2018daily activities impaired\u2019 WPAI domains (all p&lt;0.05 vs mild psoriasis). Very severe psoriasis was associated with increased \u2018work hours missed\u2019 and \u2018work hours affected\u2019 (both p&lt;0.05 vs mild psoriasis) Findings were similar by IGA. Results were confirmed by multivariable regression analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a real-world setting, more severe psoriasis, assessed by BSA and IGA, was consistently associated with worse PROs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-027535","type":"journal-article","created":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T12:15:36Z","timestamp":1555762536000},"page":"e027535","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":59,"title":["Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry"],"prefix":"10.1136","volume":"9","author":[{"given":"Bruce","family":"Strober","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut, USA"},{"name":"Probity Medical Research, Waterloo, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Corrona, LLC, Waltham, Massachusetts, USA"},{"name":"Department of Medicine, NYU School of Medicine, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Karki","sequence":"additional","affiliation":[{"name":"Corrona, LLC, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Mason","sequence":"additional","affiliation":[{"name":"Corrona, LLC, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Guo","sequence":"additional","affiliation":[{"name":"Corrona, LLC, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hur","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Herrera","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Lin","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,4,20]]},"reference":[{"key":"2025120600465213000_9.4.e027535.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.11.013"},{"key":"2025120600465213000_9.4.e027535.2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-35"},{"key":"2025120600465213000_9.4.e027535.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.04.014"},{"key":"2025120600465213000_9.4.e027535.4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/ced.12841","article-title":"Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA","volume":"41","author":"Korman","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"2025120600465213000_9.4.e027535.5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052935","article-title":"Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011","volume":"7","author":"Armstrong","year":"2012","journal-title":"PLoS One"},{"key":"2025120600465213000_9.4.e027535.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.039"},{"key":"2025120600465213000_9.4.e027535.7","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","article-title":"From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis","volume":"76","author":"Armstrong","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025120600465213000_9.4.e027535.8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.amepre.2014.02.012","article-title":"Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys","volume":"47","author":"Helmick","year":"2014","journal-title":"Am J Prev Med"},{"key":"2025120600465213000_9.4.e027535.9","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.865009"},{"issue":"suppl_2","key":"2025120600465213000_9.4.e027535.10","doi-asserted-by":"crossref","first-page":"ii65","DOI":"10.1136\/ard.2004.031237","article-title":"Psoriasis assessment tools in clinical trials","volume":"64 Suppl 2","author":"Feldman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025120600465213000_9.4.e027535.11","first-page":"147","article-title":"Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2","volume":"16","author":"Duffin","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"2025120600465213000_9.4.e027535.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"2025120600465213000_9.4.e027535.13","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"2025120600465213000_9.4.e027535.14","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"key":"2025120600465213000_9.4.e027535.15","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jaad.2012.10.055","article-title":"OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis","volume":"68","author":"Kimball","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2025120600465213000_9.4.e027535.16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jaad.2015.06.038","article-title":"Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis","volume":"73","author":"Menter","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2025120600465213000_9.4.e027535.17","first-page":"74:851-e854","article-title":"Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])","volume":"861","author":"Strober","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2025120600465213000_9.4.e027535.18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000395"},{"key":"2025120600465213000_9.4.e027535.19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150007"},{"key":"2025120600465213000_9.4.e027535.20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ad.2013.03.005","article-title":"Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study","volume":"104","author":"Daud\u00e9n","year":"2013","journal-title":"Actas Dermosifiliogr"},{"key":"2025120600465213000_9.4.e027535.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"key":"2025120600465213000_9.4.e027535.22","first-page":"199","article-title":"Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling","volume":"7","author":"Lewis-Beck","year":"2013","journal-title":"Patient Prefer Adherence"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-027535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T08:47:01Z","timestamp":1765010821000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-027535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,20]]},"published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1136\/bmjopen-2018-027535"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-027535","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}